SynthesisAmerican journal of hematology2019
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.
Synthesis in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.British journal of haematology · 2020Pooled it
- Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.American journal of hematology · 2019Pooled it
- Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.British journal of haematology · 2020Trial
- Splenomegaly and Response to Splenectomy in Immune Thrombocytopenia.Journal of clinical medicine · 2024Article
- Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective.Annals of hematology · 2023Review
- The Application of Ethnomedicine in Modulating Megakaryocyte Differentiation and Platelet Counts.International journal of molecular sciences · 2023Review
- Proteomic-Based Discovery of Predictive Biomarkers for Drug Therapy Response and Personalized Medicine in Chronic Immune Thrombocytopenia.BioMed research international · 2023Article
- A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response.Journal of thrombosis and haemostasis : JTH · 2021Article
- Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic PurpuraTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report.Annals of internal medicine · 2020Article
- Chylomicronemia from GPIHBP1 autoantibodies.Journal of lipid research · 2020Review
- Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records.Research and practice in thrombosis and haemostasis · 2020Article
- Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States.Clinical epidemiology · 2020Article
- Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient management is dependent upon physician judgment and patient preference, given both the rarity of the condition and a paucity of high-quality clinical trial evidence to inform practice guidelines. A systematic literature review was conducted to provide an up-to-date summary of studies evaluating the safety and efficacy/effectiveness of therapies used to treat adults with primary ITP in the second-line setting. Using comprehensive search strings, several medical research databases were queried. Final abstraction was performed on 186 articles. Most (75%) studies were observational in nature; nearly half were conducted in Europe. Splenectomy was the most commonly studied (n = 83, 47%), followed by rituximab (n = 49, 26%) and the thrombopoietin-receptor agonists (TPO-RAs) romiplostim (n = 34, 18%) and eltrombopag (n = 24, 13%). Twelve prospective, randomized controlled trials (RCTs) with a placebo or standard-of-care arm evaluating the safety and efficacy of either rituximab or a TPO-RA were identified and described in detail. These trials provide important information on the safety and efficacy of these treatments, and in the absence of head-to-head data, offer insights on how these therapies compare with one another in treating adult ITP in the second-line setting. This review confirms that for most second-line ITP treatment options, there remains a lack of rigorous evidence derived from RCTs, and for many treatments, there is limited evidence of any kind. The need for additional research to guide treatment choices in this setting and greater use of standardized ITP terminology are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.